Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;22(2):420-422.e2.
doi: 10.1016/j.cgh.2023.06.003. Epub 2023 Jun 17.

Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough

Sean L Lapp  1 , Meenakshi Bewtra  2 , James D Lewis  3 ; SPARC IBD Investigators
Collaborators, Affiliations

Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough

Sean L Lapp et al. Clin Gastroenterol Hepatol. 2024 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest:

Dr. Bewtra has consulted or served on an advisory board for Janssen, AbbVie, Bristol-Myers Squipp and Pfizer; and currently participates in the MedEd IBD Education Group. She has received research funding from Janssen, GlaxoSmithKline and Takeda

Dr. Lewis consulted or served on an advisory board for Eli Lilly and Company, Samsung Bioepis, UCB, Bristol-Myers Squibb, Nestle Health Science, Merck, Celgene, Janssen Pharmaceuticals, Bridge Biotherapeutics, Entasis Therapeutics, AbbVie, Pfizer, Gilead, Galapagos, Sanofi, Arena Pharmaceuticals, Protagonist Therapeutics, Amgen, and Scipher Medicine. He has had research funding from Nestle Health Science, Takeda, Janssen Pharmaceuticals, and AbbVie. He has had educational grants from Takeda and Janssen. He has performed legal work on behalf of generic manufacturers of ranitidine, including L. Perrigo Company, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Aurobindo Pharma USA, Inc., Dr. Reddy’s Laboratories, Inc., Novitium Pharma, Ranbaxy Inc. and Sun Pharmaceutical Industries, Inc., Strides Pharma, Inc., and Wockhardt USA LLC. He owns stock in Dark Canyon Labs.

Mr. Lapp reports no potential conflicts of interest

References

    1. Ye Y, Manne S, Treem WR, Bennett D. Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007–2016. Inflammatory Bowel Diseases. 2020;26(4):619–625. doi:10.1093/ibd/izz182 - DOI - PubMed
    1. Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for Active Tuberculosis in Inflammatory Bowel Disease Patients. Clinical Gastroenterology and Hepatology. 2007;5(9):1070–1075.e1. doi:10.1016/j.cgh.2007.04.007 - DOI - PubMed
    1. Vajravelu RK, Osterman MT, Aberra FN, et al. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflamm Bowel Dis. 2017;24(1):217–226. doi:10.1093/ibd/izx019 - DOI - PMC - PubMed
    1. Kim K, Jo KW, Shim TS, et al. Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors. Front Med (Lausanne). 2021;8:670242. doi:10.3389/fmed.2021.670242 - DOI - PMC - PubMed
    1. Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor. Scandinavian Journal of Gastroenterology. 2015;50(3):312–320. doi:10.3109/00365521.2014.1000960 - DOI - PubMed

Publication types

MeSH terms